Two milestones today: WhoTrades Value Stocks has 300 followers. On TradingIdea, a technical analysis charting site, two value strategies each have over 1000 subscribers. Read below:
Both investing strategies that seek deep value in an expensive stock market now have over 1000 followers. This is a milestone, but is open for more growth. Share this strategy with your friends.
Bullish coverage on Valeant Pharmaceuticals (VRX) continues. The stock rallied up around 7 percent intraday on June 1 after the company announced it will report quarterly results on June 7 before market open. Despite risks in executing its turnaround strategy, previous headwinds are dissipating. Valeant is charting a new path under CEO Papa and new management. Near-term goals include stabilizing cash flow, shedding non-core businesses and pivoting Salix and B&L towards higher growth. This must come from higher product sales, not organic growth where cost-cuts only supply temporary fixes. In the same space, Relypsa (RLYP) was previously predicted as a stock to buy at $12-13, sell at $20. The idea was right but the ranges and timing were wrong. AstraZeneca (AZN)’s ZS-9’s rejection gave bulls a reason to bid shares towards $20. Ariad Pharmaceuticals (ARIA) is charting a similar return but at a slower rate. The company is ramping up sales of two of its drugs.
In the energy sector, political and criminal risks haunt Petrobras (PBR). Better wait for these risks to dissipate before considering.
Notable picks in the
Notable pick in the